FDA-approved Anti-HIV Drugs Protease Inhibitors (PI) Non Nucleoside Reverse Transcriptase Inhibitors (nNRTI) Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTI)Protease Inhibitors (PI)Acid-reducing Agents Do Not Alter the Pharmacokinetics of Lopinavir/Ritonavir Tablet Does Earlier HAART Lead to Improved Clinical Status and Less Drug-related Toxicities? Pharmacokinetic Interaction between Atazanavir (ATV) and Lopinavir/Ritonavir (LPV/r) Lopinavir/Ritonavir Appears to Decrease the Renal Clearance of Tenofovir in HIV Patients Pilot Trial of Regimen Simplification to Atazanavir/Ritonavir Alone as Maintenance Antiretroviral TherapyPharmacokinetics of Once-daily Fosamprenavir 1400 mg plus Atazanavir 400 mg without Ritonavir Boehringer Ingelheim Announces 48-week Results from Tipranavir RESIST StudiesNew 48 Week Clinical Trial Data Report on Atazanavir with or without Ritonavir in Treatment-naive Patients Protease Inhibitor Therapy Increases Risk of Myocardial Infarction: D:A:D Study Metabolic and Morphologic Changes with PI-sparing Therapies Non Nucleoside Reverse Transcriptase Inhibitors (nNRTI)Protease Inhibitor Therapy Increases Risk of Myocardial Infarction: D:A:D Study Gene-Gene Interactions Predict Efavirenz Pharmacokinetics and Treatment Response Intensification of a Triple-nucleoside Regimen with Efavirenz or Tenofovir Efavirenz Has Minimal Long-term Neuropsychological EffectsNucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTI)The Safety of Tenofovir DF for the Treatment of HIV Infection: The First 4 Years Lopinavir/Ritonavir Appears to Decrease the Renal Clearance of Tenofovir in HIV Patients Intensification of a Triple-nucleoside Regimen with Efavirenz or Tenofovir
JUMP TO A MAIN SECTION OF WEBSITE
HOME HIV and AIDS Hepatitis C Hepatitis B
Sign Up to Receive E-mail Updates with Top New Articles
